NCT07313202尚未招募2 期
Ivarmacitinib in Advanced Solid Tumors: A Prospective, Two-Cohort, Two-Phase Exploratory Study in Patients Discontinued Due to Immune Intolerance
干预措施
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 72
- 主要终点
- Response rate to adverse reactions during the treatment cycle
研究概览
简要总结
This study is a Phase II, two-cohort, multicenter, two-stage clinical trial. It plans to enroll 72 subjects with solid tumors who discontinued prior ICI therapy due to irAE. Cohort 1 enrolls subjects with irAE resistant to or dependent on corticosteroid therapy. Subjects in Cohort 1 who achieve ≤ Grade 1 irAE resolution following treatment may then enroll in Cohort 2. Cohort 2 enrolls subjects with irAE achieving ≤ Grade 1 resolution following treatment, and deemed eligible for ICI re-initiation by the investigator. Phase I is the safety run-in phase, enrolling 6 subjects per cohort. Phase II is the expansion phase, enrolling 30 subjects per cohort.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •ECOG performance status score 0-
- •Expected survival ≥ 12 weeks.
- •Solid tumor patients who have discontinued treatment with immune checkpoint inhibitors (ICIs).
- •Treatment with ICIs may be administered as monotherapy or in combination with other therapies (including but not limited to radiotherapy, chemotherapy, targeted therapy, etc.).
- •Current Status of irAE:
- •Patients currently diagnosed with steroid-resistant or steroid-dependent immune-related adverse events (immune myocarditis, immune colitis, immune myositis-arthritis, immune skin reactions, immune hepatitis, etc.);
- •Patients with contraindications to steroid use, or who refuse continued steroid therapy due to adverse reactions following steroid administration.
- •Patients discontinued immunotherapy due to irAE (CTCAE 5.0) after receiving ≥1 line of treatment including ICIs;
- •Time since discontinuation of immunotherapy due to irAE ≤3 months;
- •irAE has resolved to ≤Grade
- •The patient still possesses certain organ and bone marrow functions:
- •Hemoglobin ≥90 g/L, neutrophil count ≥1.0 × 10^9/L, platelet count ≥75 × 10^9/L; lymphocyte count ≥0.5 × 10^9/L; coagulation function: INR, APTT, and PT all ≤1.5 × UNL;
- •Liver function: Serum total bilirubin ≤ 1.5 × upper limit of normal (ULN), aspartate aminotransferase (AST) ≤ 3 × ULN, alanine aminotransferase (ALT) ≤ 3 × ULN. For patients with immune hepatitis, specific liver function biochemical parameters are not restricted; adequate liver function is defined as Child-Pugh class A-B;
- •Renal function: Serum creatinine ≤ 1.5 × ULN or creatinine clearance ≥ 50 mL/min;
- •Or patients assessed by the investigator as having adequate organ function.
- •Organ function levels must meet the following requirements (no blood transfusion or hematopoietic growth factor therapy within 2 weeks prior to blood screening):
- •ANC ≥ 1.5 × 10⁹/L;
- •PLT ≥ 100 × 10⁹/L;
- •Hb ≥ 90 g/L;
- •TBIL ≤ 1.0 × ULN;
- •ALT and AST ≤ 2.5 × ULN;
- •BUN and Cr ≤ 1.5 × ULN.
- •All women of childbearing potential must have a negative serum pregnancy test during the screening period and must use reliable contraception from signing the informed consent form until 3 months after the last dose.
- •Subjects voluntarily participate in this study, sign the informed consent form prior to the screening process, demonstrate good compliance, and cooperate with safety follow-up.
- •The subject is judged by the investigator to be able to adhere to the study protocol.
排除标准
- •1) Individuals with allergic diseases, a history of severe drug allergies, or potential hypersensitivity to Ivarmacitinib or its components; 2) Patients diagnosed with an embolic event within 3 months prior to enrollment, excluding superficial venous thrombosis (e.g., deep vein thrombosis, pulmonary embolism, embolic stroke, myocardial infarction, or peripheral arterial insufficiency); 3) Patients with severe non-irAE-related cardiac, hepatic, renal, or systemic diseases; 4) Patients with active tuberculosis or who received live vaccines during the illness period; 5) Patients with uncontrolled infectious diseases; 6) Patients with moderate to severe heart failure (NYHA Class III/IV); 7) Hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) positive, with hepatitis B virus (HBV) deoxyribonucleic acid (DNA) exceeding 500 IU/mL or 1000 copies per milliliter (cps/mL); Hepatitis C virus (HCV) antibody (HCV-Ab) positive with HCV RNA quantitative levels exceeding the upper limit of normal for the assay; HIV antibody (Anti-HIV) positive; active syphilis. Meeting any one of the above criteria.
- •8) Previous treatment with JAK inhibitors prior to enrollment (for Cohort 1: ≤30 days of prior JAK inhibitor use, irAE resolution ≤ Grade 1, and investigator assessment permitting ICI restart; eligible for Cohort 2); 9) Cohort 2 participants with prior ICI restart therapy, including but not limited to PD-1/PD-L1 inhibitors, CTLA-4 inhibitors, etc.; 10) Patients receiving intravenous biologic therapy for other baseline autoimmune diseases; 11) Pregnant or lactating females, and males or females unwilling to use contraception; 12) Psychiatric disorders impairing study compliance; 13) Subjects deemed unsuitable for this study by the investigator shall be excluded, such as those judged to have other factors that may necessitate premature termination of the study. These include: - Concurrent treatment for other serious illnesses (including psychiatric disorders) - Severe laboratory abnormalities - Family or social circumstances that may compromise subject safety or interfere with data/sample collection.
研究组 & 干预措施
Treatment group 1：Subjects who developed resistance or dependence to hormone therapy
Experimental
干预措施: Ivarmacitinib (Drug)
Treatment group 2：Subjects whose irAE has resolved to Grade ≤1
Experimental
干预措施: Ivarmacitinib (Drug)
结局指标
主要结局
Response rate to adverse reactions during the treatment cycle
时间窗: In the study, treatment was administered on day 30 after the last dose.
Discontinuation rate due to irAE
时间窗: Follow-up visits were conducted every 30 days from the last dose of treatment until 90 days.
次要结局
未报告次要终点
研究者
相似试验
招募中
1 期
IMA401-101 – Treatment of patients with solid tumors with IMA401 TCER®, a bispecific T-cell receptor (Phase I trial); alone or in combination with checkpoint inhibitor2023-506854-19-00Immatics Biotechnologies GmbH95
招募中
1 期
A Phase 1 Study of HDM2017 in Advanced Solid TumorsNCT07274085Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.96
招募中
3 期
A Clinical Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib Versus Lazertinib as First-Line Treatment in Patients with EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer2023-506576-27-00Janssen - Cilag International170
尚未招募
2 期
Clinical Study of Adjuvant Surufatinib Therapy for Postoperative High-risk Neuroendocrine Tumors Based on the Ninth Edition of the AJCC Staging SystemNCT07279532Second Affiliated Hospital, School of Medicine, Zhejiang University35
尚未招募
2 期
A Phase 2 Randomized, Controlled Trial of QL1706 Plus Chemotherapy and Quad Shot for Driver Gene-negative Advanced Non-small Cell Lung Cancer.NCT07271602Union Hospital, Tongji Medical College, Huazhong University of Science and Technology104